<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865731</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS# 20-0147</org_study_id>
    <nct_id>NCT04865731</nct_id>
  </id_info>
  <brief_title>Dermaprazole Cream for Radiation Dermatitis in Definitive Head and Neck Cancer</brief_title>
  <official_title>A Phase II Clinical Trials of Dermaprazole Cream for Radiation Dermatitis in Definitive Head and Neck Cancer Patients (CTMS# 20-0147)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamad Hassan Fakhreddine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the study team seek to conduct a pilot clinical study to evaluate the safety&#xD;
      and efficacy of a reformulated proton pump inhibitor (PPI) cream (Dermaprazole) in definitive&#xD;
      head and neck cancer (HNC) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of clinically significant radiation dermatitis as defined as NCI CTCAE version 5 grade 2 or higher</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cancer of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Dermaprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 HNC patients who will be using Dermaprazole twice daily for 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aquaphor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 HNC patients using Aquaphor, the current clinical standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dermaprazole</intervention_name>
    <description>Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.</description>
    <arm_group_label>Dermaprazole</arm_group_label>
    <other_name>esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aquaphor</intervention_name>
    <description>Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.</description>
    <arm_group_label>Aquaphor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with head and neck malignancy (including radiation therapy to primary head&#xD;
             cancers of any histology and/or neck lymphatics, excluding brain malignancies)&#xD;
&#xD;
          -  Biopsy proven diagnosis of head and neck malignancy&#xD;
&#xD;
          -  Planned to receive definitive chemoradiation of at least 66Gy&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2&#xD;
&#xD;
          -  Written Informed Consent&#xD;
&#xD;
          -  History and Physical within 12 weeks of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior head and neck radiotherapy&#xD;
&#xD;
          -  Neoadjuvant chemotherapy&#xD;
&#xD;
          -  Any serious medical condition or illness that would preclude the safe administration&#xD;
             of the trial treatment including, but not limited to, active infection, symptomatic&#xD;
             heart failure, unstable angina, psychiatric illness or social situations that would&#xD;
             limit compliance with treatment&#xD;
&#xD;
          -  Currently taking proton pump inhibitors. Eligible if discontinues with physician&#xD;
             approval.&#xD;
&#xD;
          -  Lack of concurrent chemotherapy&#xD;
&#xD;
          -  Open wound at time of simulation&#xD;
&#xD;
          -  Known autoimmune, connective tissue, or skin disorder; or other theoretical&#xD;
             radiosensitivity to include bullous pemphigoid, dermatomyositis, lupus of the skin and&#xD;
             scleroderma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad A Fakhreddine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center - Mays Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-5798</phone>
    <email>goodwine@uthscsa.edu</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Mohamad Hassan Fakhreddine</investigator_full_name>
    <investigator_title>Clinical Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

